EC approves Telzir for HIV

The EC granted marketing approval to GlaxoSmithKline (LSE:GSK; GSK) and Vertex (VRTX) for Telzir fosamprenavir in combination with low dose ritonavir to treat HIV infection in adults in combination with other anti-HIV medications. VRTX and GSK co-discovered the protease inhibitor, which is marketed in the U.S. under the name Lexiva. ...